Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Cancer Immunol Immunother. 2019 Apr 27;68(6):999–1009. doi: 10.1007/s00262-019-02342-8

Figure 2: Progression-free survival by WHO grade, PD-L1 expression, MDSC abundance, and Treg percentage.

Figure 2:

Kaplan–Meier estimates of progression-free survival in the subgroup of patients with peripheral blood analysis divided by WHO grade (a), expression of PD-L1 on peripheral myeloid cells (b), peripheral MDSC abundance (c), and peripheral Treg percentage (d). Vertical ticks indicate time points at which patients were censored.